RANZCR ASM 2022 Adelaide, to be held on the traditional lands of the First Nations Kaurna People, warmly invites the Radiology community to the heart of Adelaide BioMed City, to join together to recognise the pivotal role of Clinical Radiology and Radiation Oncology in the healthcare of all Australians, providing an unparalleled opportunity to:
Radiation Oncology Speakers
Professor Hans Langendijk
Professor Hans Langendijk studied medicine at the Vrije Universiteit in Amsterdam. He was trained as a radiotherapist-oncologist at the Radiotherapeutic Institute Limburg in Heerlen and Maastricht. In 2000 he obtained his doctorate at Maastricht University with his thesis “Quality of Life in Non-small Cell Lung Cancer”. From 1997 to 2004, he worked as a radiotherapist-oncologist at the Radiotherapy Department of the VU Medisch Centrum in Amsterdam. During that period he further specialized in the radiotherapy of tumours in the head and neck region.
In October 2004 he works as a professor/department head at the Radiotherapy department of the University Medical Center Groningen. He is particularly interested in head and neck oncology, prevention of radiation-induced complications and the development of innovative methods for the development and clinical validation of new radiotherapy techniques, such as proton therapy.
Dr Anita Mahajan
Dr Mahajan is a professor at Mayo Clinic in the Department of Radiation Oncology. She serves as the medical director of particle therapy where she is in charge of the day-to-day operations. She is also involved in Mayo Clinic Radiation Oncology initiatives with international partners. Before moving to Mayo Clinic, she was a professor at MD Anderson Cancer Clinic in Houston. Her major interests are improving radiotherapy for paediatric patients and adult patients with brain tumours with a special interest in proton therapy and advanced delivery techniques. Dr Mahajan is an author in over 140 peer-reviewed manuscripts in high impact journals. She has been an active participant in several national and international cooperative groups and has served on the leadership committees for ASTRO, PROS, PTCOG, PTCOG-NA, and COG.
Dr Nancy Lee
Nancy Y. Lee MD, FASTRO is Vice Chairman of the Department of Radiation Oncology focusing on Experimental Therapeutics. She is also the Proton Service Chief and the Chief of the Head and Neck Radiation Oncology Service at Memorial Sloan Kettering Cancer Center. She is also the Associate Director of the Prevention Interception Program at MSKCC. Dr Lee has appointments in both Radiation Oncology Department as well as Early Drug Development Group.
Dr Lee is an internationally renowned academic physician whose research, publications (almost 300 peer reviewed papers), 3 of the best-selling target delineation books, and lectures have helped radiation oncologists across multiple radiation oncologists harness the powers of IMRT and proton therapy. She has dedicated her career to embracing technology, modernizing clinical practice, and bringing radiation oncology to the forefront of cancer medicine. She is also active in the Society for Immunotherapy of Cancer where she is a co-author of a consensus statement on immunotherapy use for head and neck cancer and has established multiple industry relationships to take command of trials combining novel therapeutic agents with radiation. Dr Lee has served on multiple ASTRO committees and editorial boards. At MSKCC, she has been a tireless advocate for patients and dedicated herself to the education of trainees (receiving multiple ARRO teaching awards and mentoring over 100 radiation oncologists around the world to successful careers of their own in academic and private practices across the country.
Her research focuses on developing novel strategies to personalize cancer treatment with the goal to improve tumor cure and quality of life after radiation treatment for head and neck cancer where she has received several NIH R01 funding, including:
(1) Designing/evaluating novel PET and/or MR imaging metrics to select best candidates for radiation dose reduction, currently the de-escalation dose is 30Gy with chemotherapy for select locally advanced Human Papilloma Virus (HPV) head and neck squamous cell carcinoma with ultimate goal of individualizing both radiation and systemic therapy; de-escalation strategies for nasopharyngeal carcinoma, HPV negative tumors; thyroid cancer.
(2) Assessing biologic targeted therapies and using biomarkers such as plasma EBV DNA to individualize treatment for nasopharyngeal, thyroid, and plasma HPV DNA to personalize oropharyngeal cancer; cell free plasma DNA or circulating tumor DNA to direct therapy across different head and neck/thyroid cancer; escalate therapy based on biologic or imaging correlates; and screening for HPV+ oropharyngeal cancer. She is principal investigator for an international NRG trial personalizing treatment for nasopharyngeal cancer using plasma EBV DNA.
(3) Establishing standard treatment guidelines for therapies such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT), and proton beam for head and neck cancer and focusing efforts on developing FLASH proton therapy with goal of further toxicity reduction.
Her top priority is to help radiation oncology continue to evolve to elevate patient care. She believes this requires actively engaging and providing opportunities for practitioners in all different settings and phases of their careers. Outside of work, Dr Lee is very involved in her church and enjoys traveling with her husband and two boys
Dr Umberto Ricardi, MD
Dr Ricardi is currently Full Professor and Chairman of Radiation Oncology at University of Turin, Italy, and Dean of the School of Medicine at the University of Turin. He is also serving as Director of the Department of Oncology at Health and Science Academic Hospital in Turin. His main areas of clinical and scientific interest include lymphoma, lung cancer, CNS tumours. He is also an expert in the development of cutting-edge technologies in radiation oncology.
Dr Ricardi has authored more than 330 full research papers, and participated as an invited speaker in a number of national and international conferences. He is active in many educational activities, both at the national and international level. He is a member of numerous national and international scientific societies and of the Steering Committee of ILROG (International Lymphoma Radiation Oncology Group). He is the immediate Past President of ESTRO (European Society for Radiotherapy and Oncology), serving in the role from April 2018–April 2020.